Imugene Limited (AU:IMU) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Imugene Limited, a company specializing in immuno-oncology, has scheduled an investor webinar to discuss recent Phase 1b clinical trial results for their blood cancer treatment, azer-cel. The webinar, featuring CEO Leslie Chong and CMO Dr. Paul Woodard, aims to update stakeholders on the progress and potential of the trial. Interested parties can join the webinar by registering online, with the opportunity to submit questions in advance and access a recording post-event.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
